
Imperagen accelerates enzyme engineering by shortening development time for enzyme variants and improving predictability of performance. Its Digital Enzyme Evolution platform combines AI-driven design, programmable biology and precision DNA editing with laboratory automation and custom robotics to identify performance hotspots and generate targeted DNA builds. The company operates as a biotechnology (B2B SaaS-like) platform serving biotechnology firms and research institutions focused on enzyme development and synthetic biology. The platform supports automated, high-throughput workflows that enable faster scale-up of enzyme-based products and workflows.

Imperagen accelerates enzyme engineering by shortening development time for enzyme variants and improving predictability of performance. Its Digital Enzyme Evolution platform combines AI-driven design, programmable biology and precision DNA editing with laboratory automation and custom robotics to identify performance hotspots and generate targeted DNA builds. The company operates as a biotechnology (B2B SaaS-like) platform serving biotechnology firms and research institutions focused on enzyme development and synthetic biology. The platform supports automated, high-throughput workflows that enable faster scale-up of enzyme-based products and workflows.
Founded: 2021
Headquarters: Manchester, UK
Product: Digital Enzyme Evolution platform (AI-driven protein design + lab automation)
Industry: Biotechnology (enzyme engineering)
Notable investors: IQ Capital; Northern Gritstone
Enzyme engineering for pharmaceuticals, industrial biotechnology, sustainable fine chemicals and life sciences research.
2021
Biotechnology
£3.5M (reported) / $4.2M (reported)
Seed round announced Aug 2022; company also received a UK R&D award (reported separately).
“Backed by UK-focused deep-tech investors IQ Capital and Northern Gritstone”